Evidence map›Paper›PMID 36211402›Full record

ArticleFrontiers in immunology2022

Primary immunodeficiencies in Bulgaria - achievements and challenges of the PID National Expert Center.

Elissaveta Naumova, Spaska Lesichkova, Veneta Milenova, Petya Yankova, Marianna Murdjeva, Snezhina Mihailova

Abstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Molecular Analysis of Dihydropteroate Synthase Gene Mutations inInternational journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elissaveta NaumovaClinic of Clinical Immunology with Stem Cell Bank, Expert Center for Rare Diseases-PID, University Hospital "Alexandrovska", Sofia, Bulgaria.
Spaska LesichkovaClinic of Clinical Immunology with Stem Cell Bank, Expert Center for Rare Diseases-PID, University Hospital "Alexandrovska", Sofia, Bulgaria.
Veneta MilenovaClinic of Clinical Immunology with Stem Cell Bank, Expert Center for Rare Diseases-PID, University Hospital "Alexandrovska", Sofia, Bulgaria.
Petya YankovaClinic of Clinical Immunology with Stem Cell Bank, Expert Center for Rare Diseases-PID, University Hospital "Alexandrovska", Sofia, Bulgaria.
Marianna MurdjevaDepartment of Microbiology and Immunology, Faculty of Pharmacy, Research Institute, Medical University, Plovdiv, Bulgaria.
Snezhina MihailovaClinic of Clinical Immunology with Stem Cell Bank, Expert Center for Rare Diseases-PID, University Hospital "Alexandrovska", Sofia, Bulgaria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tremendous progress has been made in the recognition of primary immune deficiencies (PIDs) in Bulgaria since in 2005 we have joined the J Project Central-Eastern European collaborative program. Ten years later an Expert Centre (ExpC) for Rare Diseases - Primary Immune Deficiencies at the University Hospital "Alexandrovska"- Sofia was established. In May 2017 The National Register of Patients with Rare Diseases also became operational as a database containing clinical and genetic information for Bulgarian patients with PID. The transfer of data and information on Bulgarian PID patients to the European Primary Immunodeficiency Database, managed by the European Society for Primary Immunodeficiency (ESID) has started in 2020. The total number of registered patients now is 191 (100 men and 91 women), with more than half of them being children (106; 55.5%). Regular updating of the information in the register showed that 5.2% of patients are deceased and the majority (94.8%) is a subject to continuous monitoring as it has been reported for other European countries as well. With the establishment of the ExpC, the dynamics in the diagnosis and registration of patients with PID significantly intensified. For a period of 5 years (2016-2021) 101 patients were evaluated and registered in comparison with previous period - before ExpC establishment when only 89 patients were diagnosed. The most common pathology was humoral immune deficiency (85 patients; 44.5%). Ninety-six (50.3%) of the patients underwent genetic testing, and 66. 7% had genetically confirmed diagnosis. Three of the variants have not been reported in population databases. Following genetic investigation confirmation of the initial phenotypic diagnosis was achieved in 82.8% of cases and change in the diagnosis - in 17%. Sixty-two patients were on regular replacement or specific therapy, and the rest received symptomatic and supportive treatment. In summary, we present the first epidemiological report of PIDs in Bulgaria, based on the National PID register. Data on the clinical, phenotypic and genetic characteristics of PID patients provided important information about the nature of primary immunodeficiency diseases in our country.

Indexed as

Primary Immunodeficiency DiseasesRare DiseasesBulgariaChildFemaleHumansMalePrevalenceRegistriesBulgarian PID Registryepidemiologygenetic analysisphenotypic characteristicsPrimary immunodeficiency

Identifiers

PMID36211402
PMCPMC9535737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.